Affordable Access

Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.

Authors
  • Roald, O K
  • Seem, E
Type
Published Article
Journal
British medical journal (Clinical research ed.)
Publication Date
Sep 08, 1984
Volume
289
Issue
6445
Pages
577–579
Identifiers
PMID: 6432198
Source
Medline
License
Unknown

Abstract

The serotonin receptor blocker ketanserin was given orally in a double blind crossover study to 10 patients with connective tissue disorders and Raynaud's phenomenon. Eight of the 10 patients improved clinically on ketanserin and none on placebo. Digital blood flow was assessed with laser Doppler flowmetry (LDF), photoplethysmography, and skin temperature measurements. Laser Doppler flowmetry was the most useful method, showing a significant reduction in recovery time after a standard cold provocation. Although the resting flow was not significantly improved, digital ulcers healed in four out of five patients, providing evidence of increased nutritive flow. The results of this study suggest that orally administered ketanserin may be an effective and well tolerated treatment for Raynaud's phenomenon associated with connective tissue disorders, especially scleroderma.

Report this publication

Statistics

Seen <100 times